Immunotherapy has revolutionized the landscape of cancer treatment, offering new hope to patients with various malignancies. As physicians, understanding the principles of immunotherapy is crucial to optimize patient outcomes.
Immunotherapy harnesses the body's immune system to fight cancer. It can be broadly classified into two categories: active immunotherapy, which stimulates the patient's immune system, and passive immunotherapy, which involves the administration of immune components like monoclonal antibodies.
Checkpoint inhibitors, cancer vaccines, and CAR-T cell therapies are the most common types of immunotherapy. Checkpoint inhibitors work by blocking proteins that prevent immune cells from attacking cancer cells. Cancer vaccines, on the other hand, stimulate the immune system to attack specific cancer antigens. CAR-T cell therapy involves genetically modifying T cells to enhance their cancer-fighting abilities.
Immunotherapy is indicated for a variety of cancers, including melanoma, lung, kidney, bladder, and head and neck cancers. Its efficacy varies, but it has shown remarkable results in some cases, especially in advanced melanoma where traditional therapies have failed.
Immunotherapy is generally well-tolerated, but it can cause immune-related adverse events (irAEs), such as skin rash, colitis, and endocrinopathies. Physicians should be aware of these potential side effects and manage them promptly with corticosteroids or other immunosuppressants.
In conclusion, immunotherapy is a powerful tool in the oncologist's arsenal, offering new treatment avenues for patients with various cancers. Physicians must familiarize themselves with its principles, indications, and potential side effects to effectively incorporate it into their practice.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation